Subscribe to Newsletter
Subspecialties Cornea / Ocular Surface

CXL: Seven Years Later

Corneal collagen cross-linking (CXL) has been used for the treatment of corneal ectasias since the first human pilot study was performed in 2003 in Dresden; 12 years later, it’s a well-established and well-understood procedure that continues to evolve in terms of both applications and methodology (1). To better understand the long-term safety and efficacy of the treatment, a team of ophthalmologists from Guy’s and St. Thomas’ National Health Service Foundation Trust in London have spent the last seven years conducting a prospective cohort study of patients receiving epithelium-off CXL at their hospital (2). Following the treatment, keratoconus was not observed to progress in any of the treated eyes, and the improvements observed in both topographic and wavefront parameters after one year were maintained at both five and seven years after CXL was performed.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. F Raiskup, et al., “Epi-on or Epi-off?”, The Ophthalmologist, 17, 28–33 (2015).
  2. DP O’Brart, et al., “Corneal cross-linking to halt the progression of keratoconus and corneal ectasia: seven-year follow-up”, Am J Ophthalmol, [Epub ahead of print] (2015). PMID: 26307513.
Related Case Studies
The Missing Piece of the Dry Eye Puzzle

| Contributed by Quidel

Uncovering Ocular Comorbidity

| Contributed by Quidel

Finding Ocular Surface Inflammation

| Contributed by Quidel

Related Product Profiles
Subspecialties Cornea / Ocular Surface
Tear Osmolarity – Empowering. Established. Essential.

| Contributed by TearLab

Subspecialties Cornea / Ocular Surface
Preservative-Free Cyclosporine 0.1% Ophthalmic Emulsion

| Contributed by ImprimisRx

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: